|
TW202045160A
|
|
Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
|
|
WO2020144649A1
|
|
Pharmaceutical composition comprising enzalutamide dispersed in apple sauce
|
|
PH12018502571A1
|
|
Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
|
|
SG11202003402QA
|
|
Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
|
|
CA3024872A1
|
|
Anticancer compositions
|
|
AU2016208310A1
|
|
Androgen receptor modulators and uses thereof
|
|
US2016176844A1
|
|
Processes for the preparation of a diarylthiohydantoin compound
|
|
BR112017013093A2
|
|
processes for the preparation of a diarylthiohydantoin compound
|
|
AU2015364537A1
|
|
Process for the preparation of a diarylthiohydantoin compound
|
|
BR112017011787A2
|
|
anticancer compositions
|
|
CN106999432A
|
|
Anti-cancer composition
|
|
BR112017011788A2
|
|
anticancer compositions
|
|
AU2014271290A1
|
|
Androgen receptor modulators and uses thereof
|
|
US2014088129A1
|
|
Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
|
|
KR20210012064A
|
|
Methods and compositions for determining resistance to androgen receptor therapy
|
|
PE20200725A1
|
|
CRYSTALLINE FORMS OF THE ANDROGEN RECEPTOR MODULATOR: 4- [7- (6-CYANE-5-TRIFLUOROMETHYLPYRIDIN-3-IL) -8-OXO-6-THIOXO-5,7-DIAZAESPIRO [3,4] OCT-5-IL ] -2-FLUORO-N-METHYLBENZAMIDE) (APALUTAMIDE)
|
|
JOP20200097A1
|
|
Androgen receptor modulator and uses thereof
|
|
CN104114551A
|
|
Fluorinated estrogen receptor modulators and uses thereof
|
|
BR112012031464A2
|
|
estrogen receptor modulators and their uses
|
|
GB201104288D0
|
|
Estrogen receptor modulators and uses thereof
|
